Previous 10 | Next 10 |
UroGen Pharma Ltd. (NASDAQ: URGN) is one of today's top gainers. The company's shares are currently up 26.66% on the day to $22.66. UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It of...
2023-07-28 13:41:19 ET Shares of UroGen Pharma (NASDAQ: URGN) were up more than 25% as of 1:20 p.m. ET on Friday. The biotech company announced positive phase 3 trial news for a bladder cancer therapy. The stock is up more than 152% this year. UroGen focuses on urothelial an...
2023-07-28 08:23:12 ET Tonix Pharmaceuticals Holding TNXP -43% on pricing $7M public offering . Sleep Number Corporation SNBR -25% after Q2 earning release . ParaZero Technologies ( PRZO ) -26% . Enphase Energy ENPH -15% after Q2 earning release ...
2023-07-27 19:32:42 ET Summary UroGen Pharma's stock surged by 41% after successful trials of UGN-102, a treatment for non-muscle invasive bladder cancer. UroGen plans to submit a marketing application for UGN-102 next year and has secured a $120 million private placement deal wit...
UroGen Pharma Ltd. (NASDAQ: URGN) is one of today's top gainers. The company's shares are currently up 39.73% on the day to $12.59. UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It of...
2023-07-27 10:43:35 ET UroGen Pharma ( NASDAQ: URGN ) announced Thursday that its lead product candidate, UGN-102, reached primary endpoints in two Phase 3 trials for patients with bladder cancer. The ATLAS and ENVISION trials were designed to evaluate UGN-102 in over 500 patien...
UroGen Pharma Ltd. (Nasdaq: URGN) (UroGen), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has entered into a definitive securities purchase agreement in connection with a private placement (t...
-- In ATLAS, UGN-102 Demonstrated Superiority to TURBT with a 55% Reduction of Risk for Recurrence, Progression or Death in Patients who Received UGN-102 -- -- ENVISION Showed a Complete Response Rate of 79.2% at 3-Months -- -- Side Effect Profile in ATLAS and ENVISION Con...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced the appointment of James Robinson, former President and Chief Executive Officer (CEO) of Urovant Sciences, to its Board of ...
2023-07-21 15:00:10 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
News, Short Squeeze, Breakout and More Instantly...
2024-06-25 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ord...
PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten public offering, subject to m...